Analysts at Wells Fargo & Company have initiated coverage on shares of Guardant Health (NASDAQ:GH) with an “overweight” rating and a price target of $72.00. This target implies a potential upside of 20.56% from the stock’s current price, according to a research report published on Monday.
Several other analysts have also provided insights into Guardant Health’s stock performance recently. Raymond James Financial raised their price target from $59.00 to $61.00 on July 31, assigning an “outperform” rating. Similarly, Evercore ISI upgraded the stock to a “strong-buy” rating on July 14. Mizuho increased its price target from $60.00 to $65.00, while Scotiabank adjusted its target from $57.00 to $60.00, both citing an “outperform” rating. BTIG Research maintained a “buy” rating with a price target of $70.00. Currently, one analyst has rated the stock as a Strong Buy, and eighteen have given it a Buy rating. According to MarketBeat, Guardant Health has an average rating of “Buy” and an average target price of $59.00.
Current Market Performance
As of Monday, shares of Guardant Health opened at $59.72. The company’s market capitalization stands at $7.45 billion, with a price-to-earnings ratio of -17.83 and a beta of 1.46. The stock has a 50-day moving average price of $54.89 and a 200-day moving average price of $48.49. Over the past twelve months, the stock has fluctuated between a low of $20.14 and a high of $68.00.
Guardant Health recently announced its quarterly earnings on July 30, reporting an earnings per share (EPS) of ($0.44), surpassing analysts’ consensus estimate of ($0.52) by $0.08. The company generated revenue of $232.09 million for the quarter, exceeding the expected $211.19 million and marking a 31.0% increase compared to the same quarter last year. In the previous year, the company reported an EPS of ($0.84). For the fiscal year 2025, the company has set guidance at an EPS of -2.9, according to analyst projections.
Insider Trading Activity
Recent insider trading activity has also drawn attention. On September 12, Medina Manuel Hidalgo, a director at Guardant Health, sold 2,165 shares at an average price of $54.16, resulting in a total transaction value of $117,256.40. Following this sale, Hidalgo’s ownership in the company decreased by 71.78%, leaving him with 851 shares valued at approximately $46,090.16.
Additionally, Helmy Eltoukhy, CEO of Guardant Health, sold 300,000 shares on September 9 at an average price of $59.45, totaling $17,835,000.00. After this transaction, Eltoukhy holds 2,123,499 shares valued at about $126,242,015.55, marking a 12.38% reduction in his ownership. Over the past ninety days, insiders have sold 402,691 shares worth $23,069,965, with company insiders owning 6.10% of the stock.
Institutional Investor Activity
Several institutional investors have also recently adjusted their holdings in Guardant Health. For instance, Signaturefd LLC increased its stake by 50.5% during the second quarter, now owning 635 shares worth approximately $33,000. Similarly, IFP Advisors Inc raised its holdings by 120.1%, now possessing 612 shares valued at $33,000. Other notable movements include Allworth Financial LP, which grew its stake by 358.4% and currently owns 706 shares worth around $37,000. Currently, institutional investors hold 92.60% of the total shares.
Guardant Health, Inc. specializes in precision oncology, providing blood and tissue tests, data sets, and analytics both within the United States and internationally. Their services include a variety of diagnostic tests aimed at improving cancer treatment and patient outcomes.
